DOCSLIB.ORG

2021 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 Annual Report JBM (Healthcare) Limited Incorporated in the Cayman Islands with limited liability Stock Code: 2161 Movement inspires Annual Report 2021 Corporate Information BOARD OF DIRECTORS AUTHORISED REPRESENTATIVES AUDITOR Executive Directors Mr. Wong Yat Wai, Patrick KPMG Mr. Wong Yat Wai, Patrick Dr. Chu Ka Wing Certified Public Accountants (Chief Executive Officer) Public Interest Entity Auditor Dr. Chu Ka Wing COMPANY SECRETARY registered in accordance with the Financial Reporting Council Ms. Au Man Yee, Teresa Non-executive Directors Ordinance Mr. Sum Kwong Yip, Derek REGISTERED OFFICE COMPLIANCE ADVISOR (Chairman) Cricket Square Ping An of China Capital Mr. Yim Chun Leung Hutchins Drive (Hong Kong) Company Limited Mr. Yeung Kwok Chun, Harry PO Box 2681 Grand Cayman KY1-1111 PRINCIPAL BANKERS Independent Non-executive Cayman Islands (In alphabetical order) Directors Chong Hing Bank Limited Mr. Chan Kam Chiu, Simon HONG KONG HEADQUARTERS AND Standard Chartered Bank Mr. Luk Ting Lung, Alan PRINCIPAL PLACE OF BUSINESS (Hong Kong) Limited Mr. Lau Shut Lee, Tony Unit 2303-07, 23/F The Hongkong and Shanghai Tower 1, Millennium City 1 Banking Corporation Limited 388 Kwun Tong Road AUDIT COMMITTEE Kwun Tong, Kowloon PUBLIC RELATIONS CONSULTANT Mr. Chan Kam Chiu, Simon Hong Kong Strategic Public Relations Group (Chairman) Mr. Luk Ting Lung, Alan PRINCIPAL SHARE REGISTRAR INVESTOR RELATIONS Mr. Lau Shut Lee, Tony AND TRANSFER OFFICE Email: [email protected] Conyers Trust Company REMUNERATION COMMITTEE (Cayman) Limited STOCK CODE 2161 Mr. Luk Ting Lung, Alan Cricket Square (Chairman) Hutchins Drive COMPANY WEBSITE Mr. Yim Chun Leung PO Box 2681 www.jbmhealthcare.com.hk Mr. Chan Kam Chiu, Simon Grand Cayman KY1-1111 Mr. Lau Shut Lee, Tony Cayman Islands HONG KONG BRANCH SHARE NOMINATION COMMITTEE REGISTRAR Mr. Sum Kwong Yip, Derek Tricor Investor Services Limited (Chairman) Level 54, Hopewell Centre Mr. Chan Kam Chiu, Simon 183 Queen’s Road East Mr. Luk Ting Lung, Alan Hong Kong Mr. Lau Shut Lee, Tony Contents 2 Financial Highlights 4 Chairman’s Statement 6 CEO’s Statement 8 Our Vision and Mission 9 Corporate Profile 10 Management Discussion and Analysis 27 Corporate Governance Report 40 Environmental, Social and Governance Report 51 Report of the Directors 69 Independent Auditor’s Report 73 Consolidated Statement of Profit or Loss and Other Comprehensive Income 74 Consolidated Statement of Financial Position 75 Consolidated Statement of Changes in Equity 76 Consolidated Cash Flow Statement 77 Notes to the Financial Statements 129 Four-year Financial Summary 130 Glossary 002 JBM (HEALTHCARE) LIMITED Financial Highlights Revenue Adjusted Profit Attributable to Equity Shareholders (HK$’000) (HK$’000) 450,000 60,000 400,000 350,000 50,000 300,000 40,000 250,000 200,000 30,000 150,000 20,000 100,000 50,000 10,000 0 FY2018 FY2019 FY2020 FY2021 0 FY2018 FY2019 FY2020 FY2021 Profit Attributable One-O to Equity Listing Expenses Shareholders Adjusted EBITDA Net Assets (HK$’000) (HK$’000) 1,200,000 150,000 120,000 900,000 90,000 600,000 60,000 300,000 30,000 0 0 FY2018 FY2019 FY2020 FY2021 FY2018 FY2019 FY2020 FY2021 Net Debts (Note) Net Gearing Ratio (Note) (HK$’000) 400,000 0.6 0.5 300,000 0.4 200,000 0.3 0.2 100,000 0.1 0 0.0 FY2020 FY2021 FY2020 FY2021 Note: The Group was in net cash position in FY2018 and FY2019. JBM (HEALTHCARE) LIMITED | ANNUAL REPORT 2021 003 Year ended Year ended 31 March 2021 31 March 2020 Change HK$’000 HK$’000 Revenue – Branded medicines 134,484 142,215 –5.4% – Proprietary Chinese medicines 210,851 184,009 +14.6% – Health and wellness products 51,823 55,318 –6.3% Total 397,158 381,542 +4.1% Gross profit 198,433 190,179 +4.3% Gross profit margin (%) 50.0% 49.8% Profit attributable to equity shareholders of the Company 22,600 41,022 –44.9% Profit margin attributable to equity shareholders of the Company (%) 5.7% 10.8% Adjusted EBITDA(1) 125,710 89,007 +41.2% Adjusted EBITDA margin (%)(2) 31.7% 23.3% Return on equity (%)(3) 3.7% 9.9% As at As at 31 March 2021 31 March 2020 Change HK$’000 HK$’000 Total assets 1,381,193 1,368,236 +0.9% Total liabilities 434,250 653,532 –33.6% Total equity 946,943 714,704 +32.5% (1) Adjusted EBITDA is calculated based on adjusted earnings before interest, taxes, depreciation and amortisation, where “interest” is regarded as including interest income and interest expenses and “depreciation and amortisation” is regarded as including impairment losses on non- current assets. To arrive at adjusted EBITDA the Group’s earnings are further adjusted for share of profits less losses of joint ventures and associates and non-recurring items not attributable to the operations of individual segments, including spin-off listing expenses. (2) Adjusted EBITDA margin is calculated based on adjusted EBITDA divided by revenue and multiplied by 100%. (3) Return on equity is calculated based on profit for the year divided by the arithmetic mean of the opening and closing balances of total equity in the relevant year and multiplied by 100%. 004 JBM (HEALTHCARE) LIMITED Chairman’s Statement “2020 was an extraordinary and challenging year. This is a testament to the total commitment of the management However, we have moved steadfastly with resolve and operation teams who have navigated the Company through and resilience to advance our growth strategies.” this testing time and ensured people across JBM remained focused on our purpose. JBM (Healthcare) Limited has always prided itself on being a company that caters to the healthcare needs of consumers and “Embrace transformation: We expect to see a patients alike. In the face of the current global health crisis, raised awareness and demand for over-the- we have built on this legacy. Our continued supply of branded counter and self-care products which JBM’s medicines, proprietary Chinese medicines, as well as health and wellness products has served well to fulfill the needs of general portfolio is well placed to cater for.” consumers and healthcare professionals alike. The Board is pleased to see continued progress being made towards the Company’s strategic goals in 2020. JBM’s The pandemic dominated all aspects of life and business in 2020 transformation through the spin-off from Jacobson Pharma and JBM was no exception, feeling the impact amongst both the Group to a pure-play self-care consumer-health company has operation and our people. Confronting this huge challenge, the come a long way in just two short years. We sustained a topline resolve shown by our teams in their dedication to deliver financial revenue growth in 2020 amidst the challenges the pandemic and business performance has been praiseworthy. I have been posed, delivered on our financial guidance, reconfigured our truly gratified to witness JBM deliver on our financial guidance for portfolio of businesses, and streamlined our operational the year and continue to make progress with our strategy. Over infrastructure by installing business intelligence capabilities. the course of the year, we made noteworthy advances towards Operational and financial performance was resilient through the multifaceted strategies that we set out in our 3-year growth the year. Importantly, we are seeing evidence of improved plan. We strengthened our pipelines, expanded our geographic commercial capability and our execution in this area is driving reach, built cross-border e-commerce capabilities and forged the expansion of our key growth products. Management has also strategic alliances with partners to better align JBM with our new maintained its strong focus on cost control and cash generation. strategic platform for long-term growth. JBM (HEALTHCARE) LIMITED | ANNUAL REPORT 2021 005 JBM’s capital allocation framework focuses on investing in Their efforts have meant that despite the challenges 2020 pipeline development, new product launches, and disciplined posed, we are poised to enter 2021 with our pipeline stronger, business development. our commercial execution sharper and our team spirit higher to ensure that we can deliver sustained growth for the Company. Strengthening the pipeline remains the Company’s number one priority. The strategic alliance with Kin Fung Weisen-U There is much work to be done for us to pursue our strategic Company Limited to extend the sales coverage of Weisen-U in priorities and create shareholder value. The Board will continue Singapore alongside the launch of Weisen-U Digestive Enzyme to support the Company’s priorities and ensure that they are via the cross-border e-commerce platform is a meaningful executed effectively. In this regard, I want to thank our people move towards this goal. Further collaboration with Vemedia and our partners, for without them we would not have gotten Shine Limited to represent their Excilor Skin-tag line in Taiwan this far. We will continue to count on them as we prepare for also presents an opportunity for organic growth of the current our exciting future. Last but not least, I would like to thank our business. The Board is also pleased to see the progress being shareholders and customers for their trust and support during made on cross-border e-commerce in which we are building our this unprecedented year. competence and capability to strengthen our presence and raise our revenue in the years to come. “Our People and Culture” Sum Kwong Yip, Derek Our people have shown remarkable dedication and resilience Chairman throughout the year in unprecedented circumstances. This has included those employees who have worked tirelessly in our Hong Kong, 29 June 2021 manufacturing, logistics and marketing operations throughout the pandemic in a bid to ensure that our proprietary medicines and consumer health & wellness products continued to reach patients and consumers without disruption.
Load more

Recommended publications
  • LEE BIAO LING A.K.A
    IP PHL LEE BIAO LING a.k.a. GRACE LEE, } IPC No. 14-2010-00007 Opposer, } Opposition to: } Appln. Serial No. 4-2009-002892 -versus- } Date Filed: 20 March 2009 QUINWOOD LIMITED, } TM: PO CHAI PILLS IN Respondent-Applicant } CHINESE CHARACTERS y _V NOTICE OF DECISION BENGZON NEGRE UNTALAN Counsel for Opposer 2nd Floor, SEDCCO Building, Rada corner Legaspi Streets, Legaspi Village, Makati City 1229 ANGARA ABELLO CONCEPCION RAGALA & CRUZ Counsel for Respondent- Applicant 22nd Floor, ACCRALAW Tower Second Avenue corner 30th Street, Crescent Park West, Bonifacio Global City Taguig GREETINGS: Please be informed that Decision No. 2016 - S3S dated 23 December 2016 (copy enclosed) was promulgated in the above entitled case. Pursuant to Section 2, Rule 9 of the IPOPHL Memorandum Circular No. 16-007 series of 2016, any party may appeal the decision to the Director of the Bureau of Legal Affairs within ten (10) days after receipt of the decision together with the payment of applicable fees. Taguig City, 06 January 2017. MARILYN F. RETUTAL IPRS IV Bureau of Legal Affairs Republic of the Philippines INTELLECTUAL PROPERTY OFFICE Intellectual Property Center # 28 Upper McKinley Road, McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines •www.ipophil.qov.ph T: +632-2386300 • F: +632-5539480 »[email protected] IP PHL OFFICE OF THE PHILIPPINES LEE BIAO LING a.k.a. GRACE LEE, } IPC No. 14-2010-000007 Opposer, } } Opposition to: -versus- } Application No. 4-2009-002892 Date Filed: 20 March 2009 } Trademark: "PO CHAI PILLS QUINWOOD LIMITED, } IN CHINESE CHARACTERS" Respondent-Applicant. } x x Decision No.
    [Show full text]
  • Locke Foundation Newsletter 樂居鎮基金會 Preserving Locke’S History and Legacy
    Locke Foundation Newsletter 樂居鎮基金會 Preserving Locke’s history and legacy [email protected] Fall 2020 www.locke-foundation.org Dear Friends of the Locke Foundation, Now in existence for nearly two decades, the Locke Foundation contin- ues to expand its programs, activities and offerings to the public. It is our mission to educate the public about the historic legacy of Locke and to tell the stories of California's compelling immigrant experi- ence. While Locke may be a quaint destination for a weekend drive along the meandering Sacramento River, it is a treasure trove of a by- gone era infused with whispers of human resilience and triumph over adversity. The focus on COVID-19 relief aid for urgent needs has come at the expense of smaller nonprofits, especially those supporting the arts and historical preser- vation. Already struggling to maintain operations and provide services amid the pandemic, nonprofits big and small are also facing the challenge of how to keep revenues flowing — difficult even in good times — when they can no longer count on golf tournaments, dinner galas and other charity events. COVID-19 restrictions have shut down traditional fund- raising activities for many nonprofits including the LF which had to cancel its signature events, Locke Asian Pacific Street Festival and particularly its Fall Fundraising Banquet. In order to meet our mission and provide services in our community, we rely on the gener- osity of individuals, organizations and businesses for support. Without their assistance we wouldn't be able to serve the public while accomplishing our mission goals. We ask that you make a commitment to support our annual appeal by making a cash dona- tion.
    [Show full text]
  • 有限公司 (Incorporated in the Cayman Islands with Limited Liability) (The “Company”) WARNING
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of JBM (HEALTHCARE) LIMITED 健倍苗苗（保健）有限公司 (Incorporated in the Cayman Islands with limited liability) (the “Company”) WARNING The publication of this Post Hearing Information Pack is required by The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Post Hearing Information Pack is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its sponsor, advisers or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Stock Exchange’s website does not give rise to any obligation of the Company, its sponsor, advisers or members of the underwriting syndicate to proceed with an offering in Hong Kong or any other jurisdiction.
    [Show full text]
  • China Traditional Chinese Medicine Co. Limited
    2014 INTERIM REPORT (Stock code: 00570) (Incorporated in Hong Kong with Limited Liability) China Traditional Chinese Medicine Co. Limited Co. Medicine Chinese Traditional China 中 國 中 藥 有 限 公 司 2014 中期報告 China Traditional Chinese Medicine Co. Limited 2014 INTERIM REPORT 2014 中期報告 司 公 中國中藥有限 CONTENTS CORPORATE INFORMATION 2 MANAGEMENT DISCUSSION AND ANALYSIS 3 OTHER INFORMATION 13 INDEPENDENT AUDITOR’S REPORT 20 CONSOLIDATED STATEMENT OF PROFIT OR LOSS 21 CONSOLIDATED STATEMENT OF PROFIT OR LOSS 22 AND OTHER COMPREHENSIVE INCOME CONSOLIDATED STATEMENT OF FINANCIAL POSITION 23 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 25 CONDENSED CONSOLIDATED CASH FLOW STATEMENT 27 NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT 28 China Traditional Chinese Medicine Co. Limited INTERIM REPORT 2014 1 CORPORATE INFORMATION Board of Directors Executive Directors Mr. WU Xian (Chairman) Mr. YANG Bin (Managing Director) Mr. WANG Xiaochun Non-executive Directors Mr. LIU Cunzhou Mr. ZHANG Jianhui Mr. DONG Zenghe Mr. ZHAO Dongji Independent Non-executive Directors Mr. ZHOU Bajun Mr. XIE Rong Mr. FANG Shuting Mr. YU Tze Shan Hailson Company Secretary Mr. HUEN Po Wah Audit Committee Mr. XIE Rong (Chairman) Mr. ZHOU Bajun Mr. FANG Shuting Remuneration Committee Mr. ZHOU Bajun (Chairman) Mr. LIU Cunzhou Mr. XIE Rong Mr. FANG Shuting Nomination Committee Mr. WU Xian (Chairman) Mr. YANG Bin Mr. ZHOU Bajun Mr. XIE Rong Mr. FANG Shuting Strategic Committee Mr. LIU Cunzhou (Chairman) Mr. WU Xian Mr. YANG Bin Mr. WANG Xiaochun Mr. ZHOU Bajun Mr. YU Tze Shan Hailson Registered Office Room 1601, Emperor Group Building 288 Hennessy Road, Wanchai Hong Kong Auditors KPMG Certified Public Accountants Hong Kong Share Registrar and Computershare Hong Kong Investor Services Limited Transfer Office Shop 1712-16 17th Floor, Hopewell Centre 183 Queen’s Road East Wanchai Hong Kong Principal Bankers Bank of China (Hong Kong) Limited Bank of China Limited Macau Branch Industrial and Commercial Bank of China Limited (Foshan Branch) China Merchants Bank Co., Ltd.
    [Show full text]
  • Sacramento Chinese Culture Foundation
    Sacramento Chinese Culture Foundation P. O. Box 160841, Sacramento, CA 95816 Oct-Nov 2013 www.sccfsac.org 云南游记 II (Travel through Yunnan) 香格里拉：地处青藏高原东南边缘、横断山脉南段北端， 18公里，分上虎跳、中虎跳、下虎跳三段，迂回道路25公 “三江并流”之腹地，形成独特的融雪山、峡谷、草原、 里，东面为玉龙雪 高山湖泊、原始森林和民族风情为一体的景观。 2001 山，西面为迪庆的 年，国务院批准迪庆藏族自治州中甸县更名为香格里拉 哈巴雪山，峡谷垂 县。据说中甸县同四川某县争香格里拉县名。结果让云南 直高差3790米，是 中甸县抢到了。其结果是最简单不过的更改县名为香格里 世界上最深的峡谷 拉县争到了巨大的旅游收入。 之一。江流最窄 处，仅约30余米， 悠闲的牛群慢慢的趟过小 相传猛虎下山，在 溪到远方的大草原去寻找 江中的礁石上稍一 它们的理想的草场.这种景 脚，便可腾空越过，故称虎跳峡。峡内礁石林立，有险滩 色在香格里拉郊区比比皆 21处，高达10来米的跌坎7处，瀑布10条。虎跳峡峡口海 是. 拔1800米；南岸的玉龙雪山海拔5596米，临峡一侧山体陡 远处在群山环包的山谷中 峭，几乎是绝壁，无路可寻。北岸的哈巴雪山海拔5386 的小村庄宛如淘源明笔下描写的世外桃园。如没有公路， 米。 这里的村民祖祖辈辈就会在这里繁衍。一辈子也不会知道 外面的世界。淘源不知何处去,桃花院里好耕田。 明永冰川是云南省最大、最长和末端海拔最低的山谷冰 伫立江边看着奔腾而 川，山顶冰雪终年不化。由于它所处的雪线低，气温高， 去的江水，不由想起 消融快，靠降水而生存，因而它的运动速度也快。到冬 明代大文学家杨慎的 天，它的冰舌可以从海拔5500米往下延伸到海拔2800米 名词《临江仙》。电 处，如一条银鳞玉甲的游龙，从高高的雪峰一直延伸到山 视剧《三国演义》将 下，直扑澜沧江边，离澜沧江面仅800多米。我是夏季去 此词作为插曲，使其 的.从飞来寺一早出发约两个小时左右到达。 从山脚下步 家喻户晓。 “滚滚长江东逝水，浪花淘尽英雄。是非成 行到冰舌须半天时间.如果自知体力不支,也可以租个马骑 败转头空，青山依旧在，几度夕阳红。白发渔樵江渚上， 上去。 惯看秋月春风。一壶浊酒喜相逢，古今多少事，都付笑谈 中。”意思是：滚滚长江向东流，不再回头，多少英雄像 明永冰川眺望。驱车又进一步。可以看到明永冰川的大部 翻飞的浪花般消逝，争什么是与非、成功与失败，都是短 分。走到明永冰川的冰舌。通往观川台的木桥已断。只好 暂不长久，只有青山依然存在，依然的日升日落。江上白 在断桥的尽头看冰川的最近景。据说由于全球变暖，冰川 发渔翁，早已习于四时的变化，和朋友难得见了面，痛快 每年都在退化，几十年后明永冰川可能就消失了。所以各 的畅饮一杯酒，古往今来的纷纷扰扰，都成为下酒闲谈的 位驴友尽快来看看吧。 材料。人的一生不管是皇帝，英雄还是草民就像长江里的 浪花，同历史的长河相比真是太渺小，短暂了。 长江第一湾：从梅里雪山回 作者李克来自中国北京。业余爱好旅游和写作。博克网站 丽江古镇路过长江第一弯。 http://blog.sina.com.cn/chayuanlee 奔腾而下的滚滚长江被海罗 山崖阻挡。不得不急转一个 編者按語] “Ⅴ”形大弯，折头向东北 “朝辭白帝彩雲間，千里江陵一日還。” 流去。这个“V”形大弯就是 旅行在中華大地山川湖泊, 聯想到華夏曆史逸事名人, 千 闻名的万里长江第一湾。这里水流很急，但由于江面宽 古流傳的華章詩篇往往栩栩如生地浮現於眼前。歷史和現 阔，看过去江水平缓如镜。 世相融, 夢想與真實匯聚, 或許這就是名勝古蹟經久不哀 的魅力… 虎跳峡距离丽江约60公里，这条峡谷在金沙江上游，全长 2 GMO Food : 轉基因生物 pretty much avoid any potentially harmful effects of Dr. Mao, I’ve heard GMOs men- GMOs. tioned a lot in the news and on 2. Look for non-GMO Project Verified seals.
    [Show full text]
  • Jacobson Pharma Corporation Limited 雅各臣科研製藥有限公司 (The “Company”) (Incorporated Under the Laws of the Cayman Islands with Limited Liability) WARNING
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Jacobson Pharma Corporation Limited 雅各臣科研製藥有限公司 (the “Company”) (Incorporated under the laws of the Cayman Islands with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Exchange”)/the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its sponsor, advisers or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Exchange’s website does not give rise to any obligation of the Company, its sponsor, advisers or members of the underwriting syndicate to proceed with an offering in Hong
    [Show full text]
  • QUINWOOD-LIMITED-Vs
    IP INTELLECTUAL PROPERTY OFFICE OF THE PHILIPPINES QUINWOOD LIMITED, } IPCNo. 14-2009-00149 Opposer, } Opposition to: } Appln. Serial No. 4-2008-011238 } Date Filed: 16 September 2008 -versus- } TM: "JIN LING BAO PILL } Package Label Mark" } } LEE BIAO LING a.k.a. GRACE LEE, } Respondent- Applicant. } x— ~x NOTICE OF DECISION ANGARA ABELLO CONCEPCION REGALA & CRUZ Counsel for Opposer 22nd Floor, ACCRALAW Tower Second Avenue corner 30th Street Crescent Park West Bonifacio Global City Taguig BENGZON NEGRE UNTALAN Counsel for Respondent- Applicant Second Floor SEDCCO Bldg., Rada cor. Legaspi Streets Legaspi Village, Makati City GREETINGS: Please be informed that Decision No. 2016 - T w dated December 20, 2016 (copy enclosed) was promulgated in the above entitled case. Pursuant to Section 2, Rule 9 of the IPOPHL Memorandum Circular No. 16-007 series of 2016, any party may appeal the decision to the Director of the Bureau of Legal Affairs within ten (10) days after receipt of the decision together with the payment of applicable fees. Taguig City, December 20, 2016. MARILYN F. RETUTAL IPRS IV Bureau of Legal Affairs Republic of the Philippines INTELLECTUAL PROPERTY OFFICE Intellectual Property Center # 28 Upper McKinley Road, McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines •www.ipophil.aov.ph T: +632-2386300 • F: +632-5539480 • [email protected] JFFICE OF THE PHILIPPINES QUINWOOD LIMITED, }IPC NO. 14-2009-00149 Opposer, }Opposition to: }Appln. Ser. No. 4-2008-011238 -versus- }Date Filed: 16 September 2008 }Trademark : JIN LING BAO LEE BIAO LING a.k.a. GRACE LEE, } PILL Package Label Mark Respondent-Applicant.
    [Show full text]
  • Global Offering
    Pharma Corporation Jacobson Pharma Corporation Limited 雅各臣科研製藥有限公司 (Incorporated under the laws of the Cayman Islands with limited liability) Stock Code : 2633 GLOBAL OFFERING Sole Global Coordinator Sole Sponsor Sole Bookrunner and Sole Lead Manager IMPORTANT IMPORTANT: If you are in any doubt about the contents of this prospectus, you should seek independent professional advice. Pharma Corporation Jacobson Pharma Corporation Limited 雅各臣科研製藥有限公司 (Incorporated under the laws of the Cayman Islands with limited liability) GLOBAL OFFERING Number of Offer Shares under the : 437,500,000 Shares (subject to the Global Offering Over-allotment Option) Number of Hong Kong Offer Shares : 43,752,000 Shares (subject to adjustment) Number of International Offer Shares : 393,748,000 Shares (subject to adjustment and the Over-allotment Option) Maximum Offer Price : HK$1.72 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars, subject to refund) Nominal value : HK$0.01 per Share Stock code : 2633 Sole Sponsor, Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus. A copy of this prospectus, having attached thereto the documents specified in the section headed “Documents Delivered to the Registrar of Companies and Available for Inspection” in Appendix VI to this prospectus, has been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).
    [Show full text]
  • JBM (HEALTHCARE) LIMITED ( 保健 JBM (HEALTHCARE) LIMITED ) 有限公司 健倍苗苗(保健)有限公司 (Incorporated in the Cayman Islands with Limited Liability) Stock Code: 2161
    健倍苗苗 LIMITED JBM (HEALTHCARE) ( 保健 JBM (HEALTHCARE) LIMITED ) 有限公司 健倍苗苗(保健)有限公司 (Incorporated in the Cayman Islands with limited liability) Stock Code: 2161 Sole Sponsor and Sole Bookrunner IMPORTANT If you are in any doubt about any of the contents of this prospectus, you should seek independent professional advice. JBM (HEALTHCARE) LIMITED 健倍苗苗（保健）有限公司 (Incorporated in the Cayman Islands with limited liability) PUBLIC OFFER Number of Offer Shares : 44,686,000 Shares Offer Price : HK$1.20 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) Nominal Value : HK$0.01 per Share Stock Code : 2161 Sole Sponsor, Sole Bookrunner and Joint Lead Manager Joint Lead Managers (in alphabetical order) Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus. A copy of this prospectus, having attached thereto the documents specified in the section headed “Documents Delivered to the Registrar of Companies and Available for Inspection” in Appendix V to this prospectus, has been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).
    [Show full text]
  • S3Z Dated 23 December 2016 (Copy Enclosed) Was Promulgated in the Above Entitled Case
    IP PHL JFFICE OF THE • H I LI P P I N ES LEE BIAO LING ak.a. GRACE LEE, } IPC No. 14-2010-00008 Opposer, } Opposition to: } Appln. Serial No. 4-2009-002893 -versus- } Date Filed: 20 March 2009 QUINWOOD LIMITED, } TM: PO CHAI PILLS Respondent-Applicant. } v NOTICE OF DECISION BENGZON NEGRE UNTALAN Counsel for Opposer 2nd Floor, SEDCCO Building, Rada corner Legaspi Streets, Legaspi Village, Makati City 1229 ANGARA ABELLO CONCEPCION RAGALA & CRUZ Counsel for Respondent- Applicant 22nd Floor, ACCRALAW Tower Second Avenue corner 30th Street, Crescent Park West, Bonifacio Global City Taguig GREETINGS: Please be informed that Decision No. 2016 - S3Z dated 23 December 2016 (copy enclosed) was promulgated in the above entitled case. Pursuant to Section 2, Rule 9 of the IPOPHL Memorandum Circular No. 16-007 series of 2016, any party may appeal the decision to the Director of the Bureau of Legal Affairs within ten (10) days after receipt of the decision together with the payment of applicable fees. Taguig City, 06 January 2017. MARILYN F. RETUTAL IPRS IV Bureau of Legal Affairs Republic of the Philippines INTELLECTUAL PROPERTY OFFICE Intellectual Property Center # 28 Upper McKinley Road, McKinley Hill Town Center, Fort Bonifacio, Taguig City 1634 Philippines •www.ipophil.aov.ph T: +632-2386300 • F: +632-5539480 •[email protected] LEE BIAO LING a.k.a. GRACE LEE, } IPC No. 14-2010-000008 Opposer, } } Opposition to: -versus- } Application No. 4-2009-002893 } Date Filed: 20 March 2009 } Trademark: "PO CHAI PILLS" QUINWOOD LIMITED, } Respondent-Applicant. } x x Decision No. 2016- S3Z DECISION LEE BIAO LING a.k.a.
    [Show full text]
  • Annual Report 2017 2017
    中 國 中 中國中藥控股有限公司 藥 控 股 有 限 公 司 2017 年報 China Traditional Chinese Medicine Holdings Co. Limited Co. Holdings Medicine Chinese Traditional China 年 報 ANNUAL REPORT 2017 2017 2017 Annual Report Contents Corporate Information 2 Five Year Financial Summary 3 Chairman’s Statement 5 Management Discussion and Analysis 10 Report of the Directors 31 Corporate Governance Report 45 Biographical Details of Directors and Senior Management 60 Independent Auditor’s Report 65 Consolidated Statement of Profit or Loss and Other Comprehensive Income 71 Consolidated Statement of Financial Position 73 Consolidated Statement of Changes in Equity 75 Consolidated Statement of Cash Flows 76 Notes to the Consolidated Financial Statements 78 Corporate Information BOARD OF DIRECTORS REGISTERED OFFICE Executive Directors Room 1601, Emperor Group Centre 288 Hennessy Road Mr. WU Xian (Chairman) Wanchai Mr. WANG Xiaochun (Managing Director) Hong Kong Mr. ZHAO Dongji Ms. HUANG He Tel: (852) 2854 3393 Fax: (852) 2544 1269 Non-executive Directors Email: [email protected] Mr. LIU Cunzhou STOCK CODE Mr. YANG Shanhua Ms. TANG Hua The shares of China Traditional Chinese Medicine Holdings Co. Limited are listed on The Stock Exchange of Independent Non-executive Directors Hong Kong Limited Mr. ZHOU Bajun Stock code: 00570 Mr. XIE Rong Mr. YU Tze Shan Hailson AUDITORS Mr. LO Wing Yat Deloitte Touche Tohmatsu JOINT COMPANY SECRETARY Certified Public Accountants 35/F., One Pacific Place Ms. LEUNG Suet Lun 88 Queensway Mr. ZHAO Dongji Hong Kong AUDIT COMMITTEE SHARE REGISTRAR AND TRANSFER OFFICE Mr. XIE Rong (Chairman) Mr. ZHOU Bajun Computershare Hong Kong Investor Services Limited Mr.
    [Show full text]